Methylprednisolone acetate immune suppression produces differing effects on Cryptosporidium muris oocyst production depending on when administered

Veterinary Parasitology

Volumn 149, Issue 1-2, 2007, Pages 77-84

  Miller, Thomas A ^a   Schaefer III, Frank W ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Cryptosporidium muris; Glucocorticoids; Immunosuppression; Lymphocytes; Methylprednisolone acetate; Oocysts

Indexed keywords

METHYLPREDNISOLONE ACETATE;

ANIMAL EXPERIMENT; ANTIPROTOZOAL ACTIVITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM MURIS; FEMALE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INOCULATION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; OOCYST; PARASITOSIS; SINGLE DRUG DOSE;

ANIMALS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; FECES; FEMALE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; MICE; OOCYSTS; TIME FACTORS;

CRYPTOSPORIDIUM MURIS; MUS;

EID: 34548590223     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetpar.2007.07.005     Document Type: Article

References (21)

1. Ash L.R., and Orihel T.C. Parasites: A Guide to Laboratory Procedures and Identification (1987), American Society of Clinical Pathologists Press, Chicago pp. 33-34
2. Bassler B.L., Wright M., Showalter R.E., and Silverman M.R. Intercellular signalling in Vibrio harveyi: sequence and function of genes regulating expression of luminescence. Mol. Microbiol. 9 4 (1993) 773-786
3. Cevallos A.M., Bhat N., Verdon R., Hamer D.H., Stein B., Tzipori S., Pereira M.E., Keusch G.T., and Ward H.D. Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody. Infect. Immun. 68 (2000) 5167-5175
4. Gantz T. Defensins and host defense. Science 286 (1999) 420-421
5. Hammer B.K., and Bassler B.L. Quorum sensing controls biofilm formation in Vibrio cholerae. Mol. Microbiol. 50 1 (2003) 101-104
6. Holley Jr. H.P., and Thiers B.H. Cryptosporidiosis in a patient receiving immunosuppressive therapy. Possible activation of latent infection. Dig. Dis. Sci. 31 (1986) 1004-1007
7. Iseki M., Maekawa T., Moriya K., Uni S., and Takada S. Infectivity of Cryptosporidium muris (strain RN 66) in various laboratory animals. Parasitol. Res. 75 (1989) 218-222
8. McDonald V., Deer R., Uni S., Iseki M., and Bancroft G.J. Immune responses to Cryptosporidium muris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) mice. Infect. Immun. 60 (1992) 3325-3331
9. McDonald V., Robinson H.A., Kelly J.P., and Bancroft G.J. Cryptosporidium muris in adult mice: adoptive transfer of immunity and protective roles of CD4 versus CD8 cells. Infect. Immun. 62 (1994) 2289-2294
10. McDonald V., Robinson H.A., Kelly J.P., and Bancroft G.J. Immunity to Cryptosporidium muris infection in mice is expressed through gut CD4+ intraepithelial lymphocytes. Infect. Immun. 64 (1996) 2556-2562
11. Mead J.R., Arrowood M.J., Healey M.C., and Sidwell R.W. Cryptosporidial infections in SCID mice reconstituted with human or murine lymphocytes. J. Protozool. 38 (1991) 59S-61S
12. Miller T.A., and Schaefer III F.W. Characterization of a single dose methylprednisolone acetate immune suppression model using Cryptosporidium muris and Cryptosporidium parvum. Vet. Parasitol. 141 1-2 (2006) 66-83
13. Miller T.A., and Schaefer III F.W. Characterization of a Cryptosporidium muris infection and reinfection in CF-1 mice. Vet. Parasitol. 144 (2007) 208-221
14. Miller T.A., Ware M.W., Wymer L.J., and Schaefer III F.W. Chemically and genetically immunocompromised mice are not more susceptible than immunocompetent mice to infection with Cryptosporidium muris. Vet. Parasitol. 143 (2007) 99-105
15. Navin T.R., Weber R., Vugia D.J., Rimland D., Roberts J.M., Addiss D.G., Visvesvara G.S., Wahlquist S.P., Hogan S.E., Gallagher L.E., Juranek D.D., Schwartz D.A., Wilcox C.M., Stewart J.M., Thompson III S.E., and Bryan R.T. Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: results of a 3-year longitudinal study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20 (1999) 154-159
16. O'Donoghue P.J. Cryptosporidium and cryptosporidiosis in man and animals. Int. J. Parasitol. 25 (1995) 139-195
17. Ozkul I.A., and Aydin Y. Natural Cryptosporidium muris infection of the stomach in laboratory mice. Vet. Parasitol. 55 (1994) 129-132
18. Ungar B.L., Burris J.A., Quinn C.A., and Finkelman F.D. New mouse models for chronic Cryptosporidium infection in immunodeficient hosts. Infect. Immun. 58 (1990) 961-969
19. Yoshikawa H., and Iseki M. Freeze-fracture studies of Cryptosporidium muris. J. Protozool. 38 (1991) 171S-172S
20. Yoshikawa H., and Iseki M. Freeze-fracture study of the site of attachment of Cryptosporidium muris in gastric glands. J. Protozool. 39 (1992) 539-544
21. Zhu J., Miller M.B., Vance R.E., Dziejman M., Bassler B.L., and Mekalanos J.J. Quorum-sensing regulators control virulence gene expression in Vibrio cholerae. Proc. Natl. Acad. Sci. U.S.A. 99 5 (2002) 3129-3134